| Literature DB >> 34190151 |
Liyun Zhou1, Zhenhua Jiang, Wenhui Gu, Shuangyin Han.
Abstract
ABSTRACT: We aimed to determine the clinical characteristics and prognosis factors of young patients with gastric cancer (GC).A total of 101 young patients with GC referred to Zhengzhou University People's Hospital, Henan province, China between January 1st, 2003 and June 1st, 2015 were retrospectively reviewed. The medical records included ages, genders, marital status, family history of tumors, comorbidity, Helicobacter pylori (H.pylori) infection, fibrinogen, prealbumin, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), tumor location, tumor size, TNM stage, differentiation of the tumor, WHO type, treatment method and prognostic factors effect were further assessed.The mean age of GC patients in our group was 26.0 years. The incidence was slightly higher in females (female: male = 1.1:1). Some patients had the family history of tumor and H.pylori infection (2.0%, 6.9%). The tumor sizes were mainly under 5 cm (52.4%) and the most locations were in the antrum (43.5%) and body (42.5%). A large number of patients were diagnosed as adenocarcinomas (66.3%) and the main histological of GC was poor differentiated (72.3%). Moreover, a high proportion of patients were diagnosed at the stages III-IV (61.4%), and most patients received surgery combined chemotherapy (63.4%), however, the survival outcome was poor. In univariate Cox analysis, tumor sizes, TNM stage were significantly associated with overall survival (OS) and the multivariate Cox analysis demonstrated that TNM stage was significantly associated with OS.GC in young patients has its unique biological and clinical features. A large majority of young patients were diagnosed at their advanced stages with poor prognostic. TNM stage was an independent prognostic factor for young patients with GC, early GC screening in young people should be actively promoted.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34190151 PMCID: PMC8257836 DOI: 10.1097/MD.0000000000026336
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flow chart of exclusion criteria and study design.
Baseline characteristics of young GC patients in the study.
| Variables | N (%) | |
| Patient-related | Number | 101 |
| Age (y) | ||
| Median | 26.0 | |
| Range | 17–30 | |
| Gender | ||
| Male | 48 (47.5) | |
| Female | 53 (52.5) | |
| Marital status | ||
| Married | 78 (77.2) | |
| Unmarried | 23 (22.8) | |
| Family history of tumor | ||
| Yes | 2 (2.0) | |
| No | 99 (98.0) | |
| Comorbidity | ||
| Yes | 6 (5.9) | |
| No | 95 (94.1) | |
| + | 7 (6.9) | |
| − | 80 (79.2) | |
| unknown | 14 (13.9) | |
| Fibrinogen (g/L) | ||
| Median | 3.13 | |
| Range | 1.45–17.6 | |
| Prealbumin (mg/L) | ||
| Median | 205.0 | |
| Range | 41.0–390.0 | |
| AFP (ng/mL) | ||
| Median | 2.65 | |
| Range | 0.5–219.86 | |
| CEA (ng/mL) | ||
| Median | 2.06 | |
| Range | 0.2–213.22 | |
| Tumor-related | Location | |
| Cardia | 7 (6.9) | |
| Body | 43 (42.5) | |
| Antrum | 44 (43.5) | |
| Cardia + Body + Antrum | 2 (2.0) | |
| Others | 5 (5.0) | |
| Tumor size (cm) | ||
| 0–2 | 12 (11.9) | |
| 2–5 | 41 (40.5) | |
| 5–7 | 24 (23.8) | |
| >7 | 24 (23.8) | |
| T stage | ||
| 1a | 4 (4.0) | |
| 1b | 3 (3.0) | |
| 2 | 15 (14.9) | |
| 3 | 18 (17.8) | |
| 4a | 46 (45.4) | |
| 4b | 15 (14.9) | |
| N stage | ||
| 0 | 29 (28.7) | |
| 1 | 47 (46.5) | |
| 2 | 19 (18.8) | |
| 3 | 6 (6.0) | |
| M stage | ||
| 0 | 80 (79.3) | |
| 1 | 31 (30.7) | |
| TNM | ||
| IA | 7 (6.9) | |
| IB | 4 (4.0) | |
| IIA | 11 (10.9) | |
| IIB | 17 (16.8) | |
| IIIA | 21 (20.8) | |
| IIIB | 7 (6.9) | |
| IIIC | 3 (3.0) | |
| IV | 31 (30.7) | |
| Differentiation of the tumor | ||
| Well differentiated | 10 (9.9) | |
| Moderately differentiated | 18 (17.8) | |
| Poorly differentiated | 73 (72.3) | |
| WHO type | ||
| adenocarcinoma | 67 (66.3) | |
| Signet ring | 7 (7.0) | |
| Adenocarcinoma & Signet ring | 18 (17.8) | |
| Others | 9 (8.9) | |
| Treatment-related | Surgical appoach | |
| Laparotomy | 38 (37.6) | |
| Laparoscope | 63 (62.4) | |
| Surgical treatment | ||
| Curative | 64 (63.4) | |
| Palliative | 37 (36.6) | |
| Treatment | ||
| Surgery | 35 (34.6) | |
| Surgery + chemotherapy | 64 (63.4) | |
| Lost to follow-up after surgery | 2 (2.0) |
AFP = alpha-fetoprotein, CEA = carcinoembryonic antigen, H.pylori = Helicobacter pylori.
Distant metastasis type of patients who were diagnosed with stage IV gastric cancer in the cohort.
| Distant metastasis organ involved | Patient number (N = 31) |
| Peritoneum | 3 (9.6) |
| Liver | 6 (19.4) |
| Distant lymph nodes | 7 (22.6) |
| Lung | 4 (12.9) |
| Bone | 6 (19.4) |
| Brain | 3 (9.6) |
| Kidney | 2 (6.5) |
Figure 2Kaplan–Meier curve depicting overall survival according to tumor size (A), TNM stage (B).
Univariate and multivariate Cox proportional hazard model for GC overall survival (OS) in 99 cases.
| Univariate analysis | Multivariate analysis | ||||
| Variables | N (%) | HR(95% CI) | HR(95% CI) | ||
| Gender | |||||
| male | 47 (47.5) | Reference | |||
| female | 52 (52.5) | 1.064 (0.677–1.672) | 0.789 | ||
| Maritual | |||||
| No | 31 (31.3) | Reference | |||
| Yes | 68 (68.7) | 1.169 (0.727–1.880) | 0.519 | ||
| Fibrinogen (g/L) | |||||
| ≤ 4 | 67 (67.7) | Reference | |||
| >4 | 32 (32.3) | 0.937 (0.573–1.530) | 0.794 | ||
| Prealbumin (mg/L) | |||||
| >200 | 51 (51.5) | Reference | |||
| ≤200 | 48 (48.5) | 1.279 (0.813–2.010) | 0.287 | ||
| AFP (ng/mL) | |||||
| ≤7 | 86 (86.9) | Reference | |||
| >7 | 13 (13.1) | 1.004 (0.500–2.017) | 0.991 | ||
| CEA (ng/mL) | |||||
| ≤5 | 72 (72.7) | Reference | |||
| >5 | 27 (27.3) | 0.893 (0.544–1.467) | 0.656 | ||
| Tumor size (cm) | |||||
| ≤5 | 74 (74.7) | Reference | |||
| >5 | 25 (25.3) | 0.465 (0.291–0.741) | 0.001 | 1.428 (0.828–2.462) | 0.200 |
| TNM | |||||
| I + II | 40 (40.4) | Reference | |||
| III + IV | 59 (59.6) | 0.380 (0.232–0.621) | <0.001 | 0.460 (0.259–0.817) | 0.008 |